2025-06-08-世界经济论坛-从政策到实践_商业生物经济的可行建议（英）_39页_2mb

Analysis Summary: From Policy to Practice: Actionable Recommendations for a Commercial Bioeconomy

The report outlines actionable recommendations to accelerate the transition to a commercial bioeconomy, focusing on four key areas: Regulation, Incentives, Financing, and Access and Education. Governments are urged to adopt a market-pull approach, combining innovative policies with private sector collaboration to drive bio-innovation for sustainable economic growth and national resilience. Below is a structured summary of the core recommendations and outcomes.

Overall Purpose

• The bioeconomy, bridging innovation and impact, offers transformative potential in healthcare, agriculture, energy, and manufacturing. However, scaling bio-innovations faces barriers like regulatory uncertainty, funding gaps, and limited adoption. This framework provides a roadmap for policymakers to overcome these challenges through coordinated, blended strategies.

Key Recommendations by Category

Regulation

• Objective: Accelerate safe and responsible commercialization by reducing barriers.
• Actions:
  • Expand access to testbeds (e.g., Test Farms) for empirical validation under regulatory oversight.
  • Streamline regulatory pathways (e.g., UK's RIO) to align with innovation timelines.
  • Embed technical experts in regulation-making (e.g., Japan's SciREX) to ensure evidence-based policies.
  • Enhance transparency and stakeholder engagement (e.g., Israel's Disruptive Innovation Program) to build trust and clarify processes.
• Outcome: Well-designed regulations enable faster scaling, protect consumers, and foster innovation without hindering progress.

Incentives

• Objective: Strengthen demand signals and encourage market transformation.
• Actions:
  • Implement targeted tax credits and deductions (e.g., China's incentives for biotech R&D) to reduce costs and reward early adoption.
  • Offer direct consumer incentives (e.g., Canada's Greener Homes Grant) to lower barriers for bioproducts.
  • Support large corporations in beta testing and scaling innovations through blended funding (e.g., Zambia's ethanol project).
• Outcome: Strategic incentives promote early adoption, reduce cost premiums, and create a market-pull environment for bio-innovations.

Financing

• Objective: Address funding gaps through innovative financial mechanisms.
• Actions:
  • Increase blended financing by combining public and private capital (e.g., Singapore's co-investment model) to balance risk.
  • Provide larger, earlier public funding tranches (e.g., ARPA-H's grants) to support pre-commercial stages.
  • Offer flexible, need-based financing (e.g., Germany's SPRIN-D) tailored to disruptive innovation timelines.
  • Fund shared scaling infrastructure (e.g., India's biomanufacturing hubs) to reduce capital burdens and enable pilot production.
• Outcome: De-risked funding accelerates translation from lab to market, supporting economic competitiveness and sustainability.

Access and Education

• Objective: Build a skilled workforce through education and ecosystem development.
• Actions:
  • Fund vocational training in bioeconomy-related fields (e.g., Brazil's CNPq and SENAI programs) for workforce readiness.
  • Invest in regulatory expertise and cross-border training (e.g., ASEAN-UK bio-innovation courses) to ensure agile policy adaptation.
  • Develop interconnected innovation hubs (e.g., South Korea's biocluster network) to democratize access to facilities and foster collaboration.
• Outcome: Enhanced education and ecosystems create a future-ready workforce, supporting bioeconomy growth and regional equity.

Conclusion

The bioeconomy holds significant promise for transforming industries and enhancing resilience amid geopolitical and economic uncertainties. By implementing these recommendations, governments and industries can collaboratively drive growth, innovation, and sustainability. Failure to act risks leaving the bioeconomy fragmented and underutilized. Immediate, strategic interventions are essential to position nations for global leadership in a commercial, scaled bio-economy.